hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06377319 id: 101080905 briefTitle: Decision Support System for Diagnosis and Progression of Heart Failure acronym: STRATIFYHF overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-07-31 date: 2027-07-31 date: 2024-04-22 date: 2024-04-23 name: Coventry University class: OTHER name: Newcastle University name: University of Cambridge name: University of Novi Sad name: University of Florence name: University of Regensburg name: Utrecht University name: Servicio Madrileño de Salud, Madrid, Spain briefSummary: Heart failure (HF) is a complex clinical syndrome associated with impaired heart function, poor quality of life for patients and high healthcare costs. Accurate risk stratification and early diagnosis in HF are challenging as signs and symptoms are non-specific. Here the investigators propose to address this global challenge by developing novel analytic methods for HF (STRATIFYHF). A prospective clinical study will collect patient-specific data related to medical history, a physical examination for signs and symptoms, blood tests including natriuretic peptides, an electrocardiogram (ECG), an echocardiogram (ultrasound of the heart), cardiovascular magnetic resonance imaging (MRI), demographic, socio-economic and lifestyle data along with novel technologies (cardiac output response to stress (CORS) test and voice recognition biomarkers) from individuals at-risk of developing HF and those with a confirmed diagnosis of HF. STRATIFYHF will use these data to support clinical validation of an artificial intelligence (AI)-driven decision support system (DSS) and mobile application for risk prediction, diagnosis, and progression of HF to enhance patients' quality of life and lead to more cost-effective health care. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1600 type: ESTIMATED name: Cardiac Output Response to Stress (CORS) test measure: Diagnostic accuracy of the DSS measure: Demographic and clinical predictors of risk, diagnosis, and progression of heart failure. sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377306 id: MC study briefTitle: Identifying Periods of High Training Load Considering the Menstrual Cycle Phases in Elite and Non-elite Female Athletes overallStatus: RECRUITING date: 2023-11-05 date: 2026-01-30 date: 2027-01-30 date: 2024-04-22 date: 2024-04-22 name: Wingate Institute class: OTHER name: Weizmann Institute of Science name: Kaplan Medical Center name: Ministry of Innovation, Science and Technology of Israel briefSummary: Despite a rise in the number of women participating in competitive sports, there remains a gender gap within sport and exercise science literature. Studying females involves potential "noise" through the change in hormone concentrations during the different phases of the female menstrual cycle (MC) which can potentially affect physiological parameters, thereby making study design and interpretation of findings difficult. Longitudinal data on the acute and chronic combined effects of training load and MC phases on circulating female hormones in elite and non-elite female athletes is lacking.
Finding the possible relationship between the MC phases, training load and performance or specific bio-markers for training load are of utmost importance and can assist professionals to identify periods of high load and over-training, thus preventing injuries and training adjustment. conditions: Menstrual Cycle conditions: Athletes conditions: Physical Activity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Effect of training loads and sport performance level on health and sport performance measure: Stool Microbiome measure: Serum metabolomics measure: VO2max measure: Countermovement jump measure: Flexibility measure: Grip Strength measure: Lower leg Strength measure: Blood tests measure: Knee valgus measure: Anthropometric (Height) measure: Psychological questionnaire (Positive-Affect Negative-Affect scale - PANAS) measure: Anthropometric (Weight) measure: Percentage body fat (%) measure: Psychological questionnaire (The Sport Emotion Questionnaire (SEQ) sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Wingate Institute status: RECRUITING city: Netanya country: Israel name: Yotam Shribman, B.Sc role: CONTACT phone: +972-54-5723401 email: research@wingate.org.il lat: 32.33291 lon: 34.85992 hasResults: False
nctId: NCT06377293 id: FEMH-IRB-TSAI2024 briefTitle: Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients overallStatus: NOT_YET_RECRUITING date: 2024-11 date: 2025-12 date: 2029-06 date: 2024-04-22 date: 2024-04-23 name: Far Eastern Memorial Hospital class: OTHER briefSummary: In patients with kidney failure, disturbances in bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, nutrition, and gut microbial metabolites are frequent. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, inflammation, protein-energy wasting and dysbiosis. The investigators hypothesize that therapeutic diet intervention reverses these uremic complications and thereby reduces cardiovascular risk in patients with kidney failure. In this study, the investigators crafted 4-week dialysis-specific therapeutic diet to illustrate the clinical implications of therapeutic diet for dialysis patients. conditions: End-Stage Kidney Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: A randomized, active-controlled trial with cross-over design primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Laboratory technicians who assess the study outcomes will be masked whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Dialysis-specific therapeutic diet measure: Concentrations of intact fibroblast growth factor 23 (pg/mL) measure: Concentrations of C-terminal fibroblast growth factor 23 (RU/mL) measure: Concentrations of phosphate (mg/dL) measure: Concentrations of calcium (mg/dL) measure: Concentrations of intact parathyroid hormone (pg/mL) measure: Concentrations of bone-specific alkaline phosphatase (μg/L) measure: Concentrations of procollagen-type 1 N-terminal-propeptide (P1NP) (ng/mL) measure: Concentrations of tartrate resistance acid phosphatase-5b (TRACP-5b) (mIU/ml) measure: Concentrations of alkaline phosphatase (ALP) (IU/L) measure: Concentrations of free indoxyl sulfate (mg/L) measure: Concentrations of free p-cresol sulfate (mg/L) measure: Concentrations of pre-albumin (g/dL) measure: Concentrations of albumin (g/dL) measure: Concentrations of C-reactive protein (mg/dL) measure: Absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells measure: Absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells measure: Absolute number (per μl blood) of monocytes measure: Concentrations of fetuin-A (μg/ml) measure: Concentrations of trimethylamine-N-oxide (TMAO) (μM) sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377280 id: NAV-0011 briefTitle: En Evaluation of Navina Mini, a New Low-volume Transanal Irrigation Device. overallStatus: RECRUITING date: 2024-01-18 date: 2024-10 date: 2024-12 date: 2024-04-22 date: 2024-04-22 name: Wellspect HealthCare class: INDUSTRY briefSummary: This is an un-controlled, prospective, multi center, post market clinical follow-up investigation that will enroll male and female subjects in need of bowel management with low-volume transanal irrigation (TAI) as judged by the investigator. A total of 40 investigational subjects in need of low-volume TAI will be recruited from 2-3 sites in Sweden and will be treated with Navina Mini as per product intended purpose and per instruction of use during a period of four weeks.
Participating subjects will perform three visits during the clinical investigation and will be followed for a total of four weeks. The first visit, Visit 1, will be performed at the investigational clinic to assess eligibility, collect demographics, baseline data and instruct how to use the device. Visit 2 will be performed after two weeks of treatment through telephone contact. The final visit, Visit 3, will be performed after additional two weeks of treatment, and can be performed either at the investigational clinic or through telephone contact. conditions: Bowel Dysfunction studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Navina Mini measure: Patient satisfaction measure: Assessment of clinical benefit measure: Ease of handling measure: Safety Outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Skåne University Hospital status: RECRUITING city: Malmö country: Sweden name: Louis Banka Johnson, MD role: CONTACT phone: +4640336557 email: louis_banka.johnson@med.lu.se name: Sara Strandberg role: CONTACT phone: +4640336377 email: sara.strandberg@skane.se lat: 55.60587 lon: 13.00073 hasResults: False
nctId: NCT06377267 id: ESR-20-21103 briefTitle: Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) acronym: STROBE overallStatus: RECRUITING date: 2024-02-06 date: 2024-04 date: 2025-09 date: 2024-04-22 date: 2024-04-22 name: Vall d'Hebron Institute of Oncology class: OTHER briefSummary: Background:
The study aims to address the challenge of accurately identifying patients with ovarian cancer who would benefit from poly-ADP ribose inhibitors (PARPi) as first-line maintenance therapy. While BRCA1/2-mutated epithelial ovarian cancer (EOC) patients have shown significant benefits from PARPi treatment, the efficacy in homologous recombination deficient (HRD) patients remains inconclusive. Current assays used to estimate HR status do not effectively differentiate between patients who benefit most from PARPi and those who do not, making it inefficient to treat all patients. There is a need for a more accurate HR status testing method to optimize PARPi benefit. This study aims to assess the performance of the VHIO-CARD-300 test in determining HR status compared to SOPHiA DDM™ Dx HRD Solution.
The study is a prospective, non-randomized trial designed to evaluate the concordance of the VHIO-CARD-300 test in establishing HR status compared to SOPHiA DDM™ Dx HRD Solution. Additionally, it aims to assess the association between HRD status determined by the VHIO-CARD-300 test and treatment efficacy. Patients with advanced FIGO stage III-IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer will be invited to participate. Those eligible will undergo testing with both VHIO-CARD-300 and SOPHiA DDM™ Dx HRD Solution. Patients classified as HRD positive will receive olaparib in combination with bevacizumab, while others will receive bevacizumab alone. Treatment will be administered according to approved doses, with follow-up evaluations conducted until RECIST progression. conditions: Ovarian Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Bevacizumab name: Olaparib measure: Concordance in HRD status identification between VHIO-CARD-300 test and SOPHiA DDM™ Dx HRD Solution measure: Performance Assessment of VHIO-CARD-300 Test for HR Status Identification measure: Association Between VHIO-CARD-300 Test Groups and Efficacy Outcomes(i.e., HRD positive and HRD negative) and efficacy outcomes. measure: Analysis of Progression-Free Survival (PFS) and Overall Survival (OS) in Discrepant HRD Cases measure: Safety and Tolerability of Olaparib Plus Bevacizumab measure: To evaluate the failure rate for the VHIOCARD-300 test and SOPHiA DD Dx HRD Solution. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Vall d'Hebron Institute of Oncology status: RECRUITING city: Barcelona country: Spain name: Ana Oaknin role: CONTACT lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06377254 id: BB/X015173/1 briefTitle: Multi-organ Responses to CHronic Physical Activity and INactivity acronym: CHAIN overallStatus: RECRUITING date: 2024-03-12 date: 2027-12-17 date: 2028-10-31 date: 2024-04-22 date: 2024-04-22 name: University of Nottingham class: OTHER name: Biotechnology and Biological Sciences Research Council briefSummary: Life expectancy has been increasing for the last 150 years, but the maintenance of health has not kept pace with increased lifespan, and on average, UK adults spend the last decade of life in poor-health, with major consequences for society and the individual.
nctId: NCT06377241 id: 2023-1436 id: A536000 type: OTHER domain: UW Madison id: SMPH/OPHTHAL&VIS SCI/GEN type: OTHER domain: UW Madison id: Protocol Version 2/23/2024 type: OTHER domain: UW Madison briefTitle: ScentAware and OCT in MCI vs HC overallStatus: RECRUITING date: 2024-04-15 date: 2024-06 date: 2024-06 date: 2024-04-22 date: 2024-04-22 name: University of Wisconsin, Madison class: OTHER briefSummary: The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are:
* perform two smell tests conditions: Alzheimer Disease, Early Onset studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: ScentAware name: UPSIT measure: Compare test scores of ScentAware olfactory test to the scores of the University of Pennsylvania Smell Identification Test (UPSIT) olfactory test in a clinical setting measure: Compare ScentAware test results conducted with support from clinical staff to the test results when ScentAware test was self-administered independently measure: Compare UPSIT test results conducted with support from clinical staff to the test results when ScentAware test was self-administered independently measure: Compare baseline ScentAware test scores between cohorts measure: Compare baseline UPSIT test scores between cohorts measure: Compare baseline ScentAware test scores to the retinal nerve fiber layer (RNFL) thickness measure: Compare baseline UPSIT test scores to the retinal nerve fiber layer (RNFL) thickness measure: Compare baseline ScentAware test scores to the ganglion cell layer (GCL) thickness measure: Compare baseline UPSIT test scores to the ganglion cell layer (GCL) thickness sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Wisconsin status: RECRUITING city: Madison state: Wisconsin zip: 53705 country: United States name: Amy Remm role: CONTACT phone: 608-262-3377 email: amy.remm@wisc.edu lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06377228 id: TAK-007-1001 briefTitle: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) overallStatus: NOT_YET_RECRUITING date: 2024-11-01 date: 2029-04-23 date: 2029-04-23 date: 2024-04-22 date: 2024-04-22 name: Takeda class: INDUSTRY briefSummary: The main aim of the study is to learn how well adults with refractory lupus nephritis (LN) tolerate TAK-007 and to check for side effects (adverse events).
nctId: NCT06377215 id: Pro00041729 id: R01DC020514 type: NIH link: https://reporter.nih.gov/quickSearch/R01DC020514 briefTitle: Understanding Aided Speech Perception in Noise overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2028-03-01 date: 2028-03-01 date: 2024-04-22 date: 2024-04-22 name: University of South Florida class: OTHER name: National Institute on Deafness and Other Communication Disorders (NIDCD) briefSummary: The overarching hypothesis to be evaluated using this protocol is that age-related hearing loss (ARHL) leads to shifts in the functional spatial boundaries between segregated and integrated auditory streams, and that hearing aid intervention that relies on directional processing schemes is most effective for those that have the poorest spatial sensitivity. One key component of the research design is to measure both behavioral and neurophysiological indices of an individual's spatial segregation boundary. The second key component is to measure the cost or benefit associated with hearing aid intervention in older hearing-impaired listeners. The final component is to relate cost and benefit of hearing aid intervention to spatial sensitivity measures that might predict the efficacy of clinical intervention. conditions: Hearing Impairment, Sensorineural conditions: Spatial Perception conditions: Aging conditions: Hearing Aids studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 121 type: ESTIMATED name: Open-source master hearing aid measure: Digit Identification measure: Neural Segregation measure: Minimum Audible Angle (MAA) measure: Speech Localization Error measure: Fixed Spatial Release from Masking measure: Pure-tone Air Threshold (PTac) measure: Bone Conduction Threshold (PTbc) measure: Wideband Tympanometry (Equivalent Ear Canal Volume) measure: Wideband Tympanometry (Static Peak Pressure) measure: Wideband Tympanometry (Resonant Frequency) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: USF Research Park BPB, 3802 Spectrum Boulevard, Suite 210C city: Tampa state: Florida zip: 33612 country: United States name: Erol Ozmeral, Ph.D. role: CONTACT phone: 813-974-9778 email: eozmeral@usf.edu name: Carrie Secor, Au.D. role: CONTACT phone: 813-974-4148 email: csecor@usf.edu name: Erol Ozmeral, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 27.94752 lon: -82.45843 hasResults: False
nctId: NCT06377202 id: SynKIR-110 LTFU briefTitle: Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies overallStatus: RECRUITING date: 2023-11-15 date: 2038-12-15 date: 2038-12-15 date: 2024-04-22 date: 2024-04-24 name: Verismo Therapeutics class: INDUSTRY briefSummary: The primary objective of this study is to evaluate the long-term safety of SynKIR- 110 administered to adult subjects with solid tumors expressing mesothelin. conditions: Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Number of subjects with treatment related adverse events as assessed by CTCAE v5.0 measure: Number of subjects with persistence of SynKIR-110 modified cells measure: Number of subjects with potential/suspected RCL sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pennsylvania status: RECRUITING city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Katie Elkins role: CONTACT phone: 215-615-6740 email: katie.elkins@pennmedicine.upenn.edu name: Janos Tanyi, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06377189 id: 2023-01910 briefTitle: Psychiatric Consultation-Liaison Intervention in Primary Care: A Pilot Study acronym: PLIMeC-P overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-01 date: 2025-12-01 date: 2024-04-22 date: 2024-04-22 name: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland class: OTHER name: Neuchâtel Psychiatry Centre (CNP) name: University of Lausanne Hospitals briefSummary: The pilot study on the impact of a Psychiatric Consultation-Liaison Intervention in Primary Care Medical Consultations in French-speaking Switzerland (PLIMeC-P), is a mixed method randomized controlled trial. The investigated health-related intervention is a brief Consultation-Liaison (CL) psychiatry intervention in primary care.
Primary Care Physicians (PCPs) have a key role in preventing, detecting, and managing mental disorders. Therefore, the optimization of both the quality of their interventions and their cooperation with psychiatric and psychological care networks are important challenges. It is well demonstrated that multidisciplinary interventions improve the efficacy of mental health care, CL psychiatry being one such type of intervention. Therefore, community CL-psychiatry, for example in private primary care group practices, are rare. The impact of such community, primary care CL-psychiatry interventions, should be investigated.
The mixed methods randomized controlled trial PLIMeC study will examine the impact of a CL-psychiatric intervention in primary care settings, for newly reported mental illness, versus a Treatment As Usual (TAU) control arm. The intervention consists of a CL-psychiatric intervention into private medical practices, provided to patients suffering from mental health problems, a group of patients generally under-treated. The CL-psychiatrist will receive and discuss PCPs' referrals for patients with mental distress, who don't have a psychiatric follow-up. After a brief intervention (1-4 sessions), feedback conjoint (PCP-psychiatrist) session will be organized, to complete the intervention and provide proposals.
The pilot study (PLIMeC-P) will determine whether the main planned study (PLIMeC) is feasible and practicable. It will be conducted on two sites, the Neuchâtel Psychiatry Centre (CNP) and the North-west Adult Psychiatry Service (SPANO), Department of Psychiatry of CHUV, Yverdon. For the pilot study (PLIMeC-P), 15 eligible participants are expected for each group, 30 participants in total. They will be recruited in three private primary care group practices. After eligibility and randomization 15 participants will be included for the intervention arm (brief CL-psychiatric intervention) and 15 for the control arm (TAU). The expected number of participants for the main trial (PLIMeC) will be estimated through analysis of the initial results of the PLIMeC-P. conditions: Mental Health Issue conditions: Depression/Anxiety conditions: Quality of Life conditions: Psychosomatic Disorders conditions: Patients Lived Experiences conditions: Doctor-Patient Relation conditions: Collaboration studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In order to answer the research question of the PLIMeC-P (pilot study), aiming to determine the feasibility and practicability of the main PLIMeC study, in the initial phase, the statistical procedures will be limited to questions of practicability and quality.